Business ❯ Pharmaceuticals

Clinical Trials

Drug Development Regulatory Affairs Product Development Vaccine Development Eli Lilly Experimental Drug Early Stage Trials Blarcamesine Drug Approval Veterinary Pharmaceuticals Regulatory Approvals Oncology Phase I/II Studies Investigational Drugs Phase 3 Studies Cardiovascular Drugs Market Analysis Neuropsychiatric Disorders Weight Loss Drugs Amyotrophic Lateral Sclerosis mRNA Technology Obesity Treatments Melanoma Treatment Drug Efficacy Cardiovascular Research Market Impact Regulatory Compliance Novo Nordisk Cancer Treatments

Novo Nordisk’s Semaglutide Eases Childhood Obesity as Heart-Drug Trials Are Halted

A clear pediatric efficacy signal prompting regulatory review, increased safety scrutiny and questions about Novo’s ability to grow beyond its GLP-1 franchise.

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

NeuroThera Wins Conditional TSX Approval to Acquire CliniQuantum

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

Bayer Stroke Drug Asundexian Hits Phase III Goals, Shares Jump